Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LAF 237

Known as: LAF-237, LAF237 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
  • W. Liu, S. Xie, +5 authors T. Park
  • Journal of Pharmacology and Experimental…
  • 2012
  • Corpus ID: 9594878
Dipeptidyl peptidase (DPP) IV inhibitors are probably beneficial for preventing diabetic complication and modulating glucagon… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2012
2012
Aim. To investigate the combination effects and mechanisms of valsartan (angiotensin II type 1 receptor blocker) and LAF237 (DPP… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2011
Highly Cited
2011
Fibroblast activation protein-α (FAP) is a cell surface, serine protease of the post-prolyl peptidase family that is expressed in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2008
Highly Cited
2008
LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] is an inhibitor of dipeptidyl peptidase IV that delays the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2006
Review
2006
  • A. Barnett
  • International journal of clinical practice
  • 2006
  • Corpus ID: 2645092
The dipeptidyl peptidase 4 (DPP‐4) inhibitors enhance the body's own ability to control blood glucose by increasing the active… Expand
Highly Cited
2005
Highly Cited
2005
Objective:  A novel treatment option for diabetic patients is the enhancement of incretin hormone activity by inhibition of the… Expand
2005
2005
LAF237 is a selective DPP‐4 inhibitor under development as an anti‐diabetic agents. The objective of this study was to assess the… Expand
Highly Cited
2004
Highly Cited
2004
This study characterizes the high-fat diet-fed mouse as a model for impaired glucose tolerance (IGT) and type 2 diabetes. Female… Expand
  • figure 1
  • figure 3
  • figure 2
Highly Cited
2004
Highly Cited
2004
OBJECTIVE To assess the 12- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Highly Cited
2004
Highly Cited
2004
The stimulation of insulin vs. inhibition of glucagon secretion in relation to the antidiabetic action of glucagon-like peptide-1… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3